Validating A Better ALS Biomarker With Coya's Fred Grossman clinicalleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalleader.com Daily Mail and Mail on Sunday newspapers.
Major Donation to Houston Methodist for Brain Science | NewsRadio 740 KTRH | KTRH Local Houston and Texas News iheart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iheart.com Daily Mail and Mail on Sunday newspapers.
Inside Myasthenia Gravis: Where Providers and Patients Diverge on Defining Treatment Success healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy of low-dose interleukin-2 (ld IL-2) in 8 patients with mild-to-moderate AD. The study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital.
Coya’s investigational low-dose interleukin-2 (ld IL-2) for subcutaneous administration has been designed to enhance in vivo the anti-inflammatory function of regulatory T cells (Tregs).
Treg dysfunction has been associated with increased neuroinflammation, which is observed in AD and other neurodegenerative diseases, and may contribute to disease severity and progression.
Coya Therapeutics, Inc.: Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Alzheimer's Association International Conference (AAIC) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.